Fractyl Health Announces the Initiation of a Global Registry Study of the Revita System™ in Patients With Inadequately Controlled Type 2 Diabetes (T2D)
Fractyl Health today announces the initiation of its Revita® Global Registry Program in Germany.
Uncategorized
Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting
–– Roche, Genentech and partners embark on global prevalence research, trend-spotting with digital analysis, and telehealth initiatives to assess & address deterrents to brain health to better understand holistic health journeys of patients with neurologic diseases.
Descarga Airbnb APK para Huawei y aprende en qué se diferencia de otras apps
Explorar el mundo es una auténtica experiencia. Sin embargo, encontrar el alojamiento perfecto puede ser un dolor de cabeza. Por suerte, con Airbnb el proceso es más sencillo, pues es la mejor aplicación para buscar estancias cómodas y a un precio muy asequible. …
Descarga Airbnb APK para Huawei y aprende en qué se diferencia de otras apps Read More »
Sphere Fluidics Begins Work With Partners on 3DSecret Program to Investigate Mechanisms of Metastasis in Cancer
Sphere Fluidics announced its involvement in 3DSecret, a four-year research project funded through the European Innovation Council’s Pathfinder Open 2022, established under Horizon Europe, the EU’s key funding program for research and innovation.
ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Nitrofurantoin Oral Suspension USP, 25 mg/5 ml.
Mallinckrodt to Report Earnings Results for First Quarter 2023
Mallinckrodt plc, a global specialty pharmaceutical company, announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023.
Mallinckrodt to Report Earnings Results for First Quarter 2023 Read More »
Lilly to Divest BAQSIMI to Amphastar
Eli Lilly and Company and Amphastar Pharmaceuticals, Inc. have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product.
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.
¿Por qué tenemos diferentes colores de ojo?
En este Short averiguaremos qué factores biológicos influyen en el color de los ojos. …
Belief BioMed Announces a Key Milestone of Dosing Completion for All Subjects in its Registrational Clinical Trial of BBM-H901
Belief BioMed Group announced the completion of patient dosing in its Phase III Registrational Clinical Trial of BBM-H901, a gene therapy for Hemophilia B developed and manufactured in-house by Shanghai Belief-Delivery Biomed Co., Ltd., its wholly owned subsidiary.